AcuTemp unit remains the only FAA-approved container for domestic US use
Continental Airlines Cargo has made a “selection” of the AcuTemp RKN container for use on its cargo jets, says CSafe LLC (Dayton, OH) in a recent announcement. CSafe is the marketing j.v. between AcuTemp Thermal Systems (Dayton, OH) and AmSafe, Inc. (Phoenix), the two companies that developed the RKN unit. “Our selection by Continental reinforces CSafe’s position as a premier player in the active temperature marketplace and expands customers’ options for temperature critical transportation,” said Steve Boyd, CSafe director of business development.
But the real story here might be Continental’s aggressive positioning to capture more of the cold chain market. Last fall, Continental became the first cargo air carrier to be qualified internationally under a “Qualified Envirotainer Provider Training” (QEP) program run by Envirotainer (Lagga Marma, Sweden), which happens to be the only direct competitor to CSafe. “Continental is determined to offer our customers the most advanced cold-chain technology available,” said Mark Mohr, Continental’s manager, product development and specialty sales. “The AcuTemp RKN represents the latest addition to our ever-growing arsenal of temperature-sensitive shipping capabilities.”
Envirotainer’s and CSafe’s containers are unit-load devices that contain a pallet-sized (more or less) shipment of pharmaceuticals. Both can be “active,” meaning that they have onboard refrigerators (or, if necessary, heaters) that can be powered from batteries or plugged in. (Similar “passive” devices use dry ice or refrigerated phase-change material to maintain temperature). CSafe’s unit is FAA-rated; Envirotainer’s, although on the market longer, await FAA approval.
An Exploration of Compounding Practices
May 22nd 2025In a Q&A with Pharma Commerce, Kurt Lunkwitz, ProRx Pharma’s COO, uncovers the stringent requirements that 503B outsourcing facilities must abide by under the Drug Quality and Security Act, while also shedding light on the FDA’s impact when it comes to improving the safety, quality, and trust in compounded drugs.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.